A comparison with other AML groups with intermediate or adverse risk shows that these NPM1-mut AML patients with adverse cytogenetics are more similar to patients with intermediate risk than to those with adverse risk [38]. The gene discussed is NPM1; the disease is acute myeloid leukemia.